ELV Forensic analysis

Trading Setup & Entry Strategy

Elevance Health (ELV) is currently exhibiting strong bullish momentum, but the RSI of 77.74 indicates it is deeply overbought and prime for a short-term correction. We are currently positioned to observe a pullback rather than chasing a blow-off top.

• >Entry Zone: Wait for a cooling-off period. Scale in with 30% of position between $385.00 – $388.00 (retesting the 10-day SMA). Add 40% at $375.00 (secondary support).
• >Stop Loss: Hard stop at $365.00 (below the recent congestion zone and 50-day SMA) to protect against a total trend reversal.
• >Take Profit: Target $415.00 (Bollinger Upper Band extension) for partials and $425.00 for the final exit.
• >Risk/Reward: Targeted 1:2.4 R/R ratio.

Executive Summary

ELV is showing resilient growth in its Carelon segments, offsetting moderate pressure from Medicaid redetermination-driven morbidity. Despite a Q1 EPS beat and raised guidance, the stock's recent 22.6% 20-day surge creates an overextended technical profile that necessitates patience for an entry point.

Financial Health & Forensics

ELV's Q1 2026 earnings reflect a mixed fundamental picture. While operating revenue grew 1.5% to $49.49B, net income fell 19.4% due to a massive $935M accrual related to the CMS risk adjustment data sanction threat.

• >Revenue Quality: Strong organic growth in Carelon Rx/Services; however, the $935M CMS liability represents a significant red flag regarding operational compliance and forecasting accuracy.
• >Balance Sheet: Solid liquidity with $9.66B in Cash/Equivalents. However, the $31.12B long-term debt load requires diligent monitoring in a higher-for-longer rate environment.

Technical Analysis & Trade Timing

• >Trend: Bullish, but currently experiencing PEAK_FOMO with an RSI of 77.74.
• >Indicators: Price is significantly above the 50-day and 200-day SMAs ($330.59), signaling a massive deviation from the mean.
• >Reconciliation: While the fundamental growth thesis is intact, the technicals demand a pullback. We treat the recent 22.6% rally as a 'correction-ready' setup.

Short-Term Trading Strategy (2-5 Days)

• >Timeframe: Swing Trade (2–5 Days)
• >Position Size: 3% of portfolio.
• >Scaling: Enter 30% at $388.00, add 40% on test of $380.00.
• >Max Hold: 7 days. If the stock fails to consolidate above $385.00, cash out.

One-Liner Thesis

ELV is a fundamental compounder currently suffering from technical overextension; we seek to acquire exposure during the inevitable mean reversion toward the 10-day SMA.